REMS Abuse Website: Has It Changed The Behavior Of Innovators?
Executive Summary
Updated numbers from the US FDA's REMS abuse website show that Celgene has received two additional safety determination letters, raising question's about whether the public list has changed the practices of brand companies hindering generic company access to samples.
You may also be interested in...
Generic Sample Access Process For REMS-Protected Brands Now Includes Agency Timeline
US FDA has 120 days to review generic sponsors’ requests for letters to help them obtain product samples, but will not send them to the reference product company.
Generic Sample Access Process For REMS-Protected Brands Now Includes Agency Timeline
US FDA has 120 days to review generic sponsors’ requests for letters to help them obtain product samples, but will not send them to the reference product company.
Gottlieb: Brand Industry 'Gaming' Tactics Have Shifted
US FDA's focus on areas such as REMS abuse may have prompted certain brand sponsors to shift their focus to the commercial space to keep generic competition off the market, former commissioner Scott Gottlieb tells the Association for Accessible Medicines.